Nephrotoxicity of HAART

AIDS Research and Treatment

Volumn 2011, Issue , 2011, Pages

  Kalyesubula, Robert ^a   Perazella, Mark A ^b  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863852626     PISSN: 20901240     EISSN: 20901259     Source Type: Journal    
DOI: 10.1155/2011/562790     Document Type: Review

References (109)

1. Mwagomba B., Zachariah R., Massaquoi M., Mortality reduction associated with HIV/AIDS care and antiretroviral treatment in rural Malawi: evidence from registers, coffin sales and funerals. PloS one 2010 5 5 e10452 2-s2.0-77956276395 10.1371/journal.pone.0010452
2. Montaner J. S. G., jmontaner@cfenet.ubc.ca Wood E., Kerr T., Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. Journal of Acquired Immune Deficiency Syndromes 2010 55 supplement 1 S5 S9 10.1097/QAI.0b013e3181f9c1f0
3. Palella F. J. Jr., Delaney K. M., Loveless M. O., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. The New England Journal of Medicine 1998 338 13 853 860 (Pubitemid 28135961)
4. Moreno-Cuerda V. J., Morales-Conejo M., Rubio R., Antiretroviral treatment associated life-threatening adverse events. Medicina Clinica 2006 126 19 744 749 2-s2.0-33745671658 10.1157/13088948 (Pubitemid 43967210)
5. Campbell L. J., Ibrahim F., Fisher M., Holt S. G., Hendry B. M., Post F. A., Spectrum of chronic kidney disease in HIV-infected patients. HIV Medicine 2009 10 6 329 336 2-s2.0-67449110135 10.1111/j.1468-1293.2008.00691.x
6. Hegde S., Singh C., Ohare B., HIV-associated nephropathy in the setting of maximal virologic suppression. Pediatric Nephrology 2011 26 6 973 977
7. Choi A. I., Shlipak M. G., Hunt P. W., Martin J. N., Deeks S. G., HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009 23 16 2143 2149
8. Lucas G. M., Lau B., Atta M. G., Fine D. M., Keruly J., Moore R. D., Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. Journal of Infectious Diseases 2008 197 11 1548 1557 2-s2.0-43949135497 10.1086/587994 (Pubitemid 351706485)
9. Kopp J. B., Smith M. W., Nelson G. W., MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nature Genetics 2008 40 10 1175 1184 2-s2.0-52949110955 10.1038/ng.226
10. Tzur S., Rosset S., Shemer R., Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Human Genetics 2010 128 3 345 350 2-s2.0-77956063973 10.1007/s00439-010-0861-0
11. Gerntholtz T. E., Goetsch S. J. W., Katz I., HIV-related nephropathy: a South African perspective. Kidney International 2006 69 10 1885 1891 2-s2.0-33646710870 10.1038/sj.ki.5000351 (Pubitemid 43739220)
12. Tamkus D., Jajeh A., Osafo D., Hadad L., Bhanot B., Yogore M. G. III, Thrombotic microangiopathy syndrome as an AIDS-defining illness: the experience of J. Stroger hospital of Cook county. Clinical Advances in Hematology and Oncology 2006 4 2 145 149 2-s2.0-33645346503
13. Brady M. T., Oleske J. M., Williams P. L., Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. Journal of Acquired Immune Deficiency Syndromes 2010 53 1 86 94 2-s2.0-74049136153 10.1097/QAI.0b013e3181b9869f
14. Pollok R. C. G., Francis N., Cliff S., Nelson N., Gazzard B., Kaposi's sarcoma in the kidney. International Journal of STD and AIDS 1995 6 4 289 290 2-s2.0-0029046495
15. Wyatt C. M., Malvestutto C., Coca S. G., Klotman P. E., Parikh C. R., The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008 22 14 1799 1807 2-s2.0-66349107162 10.1097/QAD.0b013e32830e0152
16. Fischer M. J., Wyatt C. M., Gordon K., Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. Journal of Acquired Immune Deficiency Syndromes 2010 53 2 222 226 2-s2.0-75649125597 10.1097/QAI. 0b013e3181b980d4
17. Szczech L. A., Gupta S. K., Habash R., The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney International 2004 66 3 1145 1152 2-s2.0-4344705225 10.1111/j.1523-1755.2004. 00865.x (Pubitemid 39121021)
18. Roe J., Campbell L. J., Ibrahim F., Hendry B. M., Post F. A., HIV care and the incidence of acute renal failure. Clinical Infectious Diseases 2008 47 2 242 249 2-s2.0-46349102258 10.1086/589296 (Pubitemid 351920627)
19. Wyatt C. M., Arons R. R., Klotman P. E., Klotman M. E., Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006 20 4 561 565 2-s2.0-33644916614 10.1097/01.aids.0000210610.52836.07 (Pubitemid 43731600)
20. Naicker S., Aboud O., Gharbi M. B., Epidemiology of acute kidney injury in Africa. Seminars in Nephrology 2008 28 4 348 353 2-s2.0-46749119834 10.1016/j.semnephrol.2008.04.003 (Pubitemid 351952284)
21. Atta M. G., Deray G., Lucas G. M., Antiretroviral nephrotoxicities. Seminars in Nephrology 2008 28 6 563 575 2-s2.0-55649102973 10.1016/j. semnephrol.2008.08.009
22. Reid A., Stöhr W., Walker A. S., Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. Clinical Infectious Diseases 2008 46 8 1271 1281 2-s2.0-42549083460 10.1086/533468 (Pubitemid 351589914)
23. Jones R., Stebbing J., Nelson M., Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. Journal of Acquired Immune Deficiency Syndromes 2004 37 4 1489 1495 2-s2.0-10044236429 10.1097/01.qai.0000138983.45235.02 (Pubitemid 39602339)
24. Izzedine H., Isnard-Bagnis C., Hulot J. S., Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004 18 7 1074 1076 2-s2.0-2342639060 10.1097/00002030-200404300-00019 (Pubitemid 38591202)
25. Earle K. E., Seneviratne T., Shaker J., Shoback D., Fanconi's syndrome in HIV+ adults: report of three cases and literature review. Journal of Bone and Mineral Research 2004 19 5 714 721 2-s2.0-3242807577 10.1359/jbmr.2004.19.5.714 (Pubitemid 41094381)
26. Peyrière H., Reynes J., Rouanet I., Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. Journal of Acquired Immune Deficiency Syndromes 2004 35 3 269 273 2-s2.0-10744221111 10.1097/00126334- 200403010-00007 (Pubitemid 38280652)
27. Cooper R. D., Wiebe N., Smith N., Keiser P., Naicker S., Tonelli M., Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in hiv-infected patients. Clinical Infectious Diseases 2010 51 5 496 505 2-s2.0-77955786301 10.1086/655681
28. Overton E. T., Nurutdinova D., Freeman J., Seyfried W., Mondy K. E., Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Medicine 2009 10 6 343 350 2-s2.0-67449149056 10.1111/j.1468-1293.2009.00693.x
29. Crum-Cianflone N., Ganesan A., Teneza-Mora N., Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care and STDs 2010 24 6 353 360 2-s2.0-77954189876 10.1089/apc.2009.0326
30. Nelson M., Azwa A., Sokwala A., Harania R. S., Stebbing J., Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS 2008 22 11 1374 1376 2-s2.0-49849090481 10.1097/QAD.0b013e328303be50
31. Zimmermann A. E., Pizzoferrato T., Bedford J., Morris A., Hoffman R., Braden G., Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clinical Infectious Diseases 2006 42 2 283 290 2-s2.0-30144434319 10.1086/499048 (Pubitemid 43054205)
32. Couzigou C., Daudon M., Meynard J. L., Urolithiasis in HIV-positive patients treated with atazanavir. Clinical Infectious Diseases 2007 45 8 e105 e108 2-s2.0-34848881299 10.1086/521930 (Pubitemid 47580370)
33. Murphy M. D., O'Hearn M., Chou S., Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clinical Infectious Diseases 2003 36 8 1082 1085 2-s2.0-0037447344 10.1086/368313 (Pubitemid 36513297)
34. Bonnet F., Balestre E., Bernardin E., Pellegrin J. L., Neau D., Dabis F., Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999-2003. Antiviral Chemistry and Chemotherapy 2005 16 1 63 67 2-s2.0-17144429710 (Pubitemid 40754329)
35. Perazella M. A., Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney International 2010 78 11 1060 1063 2-s2.0-78349239966 10.1038/ki.2010.344
36. WHO, Antiretroviral Therapy for HIV Infection in Adults and Adolescents 2010 Austria WHO Press Recommendations for a Public Health Approach
37. Sax P. E., Tierney C., Collier A. C., Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. The New England Journal of Medicine 2009 361 23 2230 2240 2-s2.0-73349134686 10.1056/NEJMoa0906768
38. Garvey L., Latch N., Erlwein O. W., The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antiviral Therapy 2010 15 2 213 218 2-s2.0-77950663633 10.3851/IMP1517
39. Berns J. S., Cohen R. M., Stumacher R. J., Rudnick M. R., Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. Journal of the American Society of Nephrology 1990 1 9 1061 1080 2-s2.0-0026128545
40. Joshi M. K., Liu H. H., Acute rhabdomyolysis and renal failure in HIV-infected patients: risk factors, presentation, and pathophysiology. AIDS Patient Care and STDs 2000 14 10 541 548 2-s2.0-0033770940 10.1089/ 108729100750018308
41. Dori L., Buonomini A. R., Viscione M., Sarmati L., Andreoni M., A case of rhabdomiolysis associated with raltegravir use. AIDS 2010 24 3 473 475 2-s2.0-75649112262 10.1097/QAD.0b013e328334cc4a
42. Zembower T. R., Gerzenshtein L., Coleman K., Palella F. J. Jr., Severe rhabdomyolysis associated with raltegravir use. AIDS 2008 22 11 1382 1384 2-s2.0-49849103584 10.1097/QAD.0b013e328303be40
43. Peraldi M. N., Maslo C., Akposso K., Mougenot B., Rondeau E., Sraer J. D., Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies. Nephrology Dialysis Transplantation 1999 14 6 1578 1585 2-s2.0-0033016111 10.1093/ndt/14.6.1578 (Pubitemid 29241763)
44. Kiser J. J., Carten M. L., Aquilante C. L., The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clinical Pharmacology and Therapeutics 2008 83 2 265 272 2-s2.0-38349171607 10.1038/sj.clpt.6100269
45. Ray A. S., Cihlar T., Robinson K. L., Mechanism of active renal tubular efflux of tenofovir. Antimicrobial Agents and Chemotherapy 2006 50 10 3297 3304 2-s2.0-33749531758 10.1128/AAC.00251-06 (Pubitemid 44527501)
46. Deeks E. D., Perry C. M., Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Drugs 2010 70 17 2315 2338 2-s2.0-78549263792 10.2165/11203800-000000000-00000
47. Current DHHS treatment guidelines for first time therapy. Positively Aware 2009 20 2 61
48. Jimenez-Nacher I., Garcia B., Barreiro P., Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. Journal of Antimicrobial Chemotherapy 2008 62 4 816 822 10.1093/jac/dkn252
49. de Vries-Sluijs T. E. M., Reijnders J. G. P., Hansen B. E., Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010 139 6 1934 1941 2-s2.0-78649711070 10.1053/j.gastro.2010.08.045
50. Grant R. M., Lama J. R., Anderson P. L., Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine 2010 363 27 2587 2599 2-s2.0-78650549662 10.1056/NEJMoa1011205
51. Smith D. K., Grant R. M., Weidle P. J., Lansky A., Mermin J., Fenton K. A., Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. Morbidity and Mortality Weekly Report 2011 60 3 65 68
52. Kiser J. J., Carten M. L., Aquilante C. L., The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clinical Pharmacology and Therapeutics 2008 83 2 265 272 2-s2.0-38349171607 10.1038/sj.clpt.6100269
53. Imaoka T., Kusuhara H., Adachi M., Schuetz J. D., Takeuchi K., Sugiyama Y., Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Molecular Pharmacology 2007 71 2 619 627 2-s2.0-33846420624 10.1124/mol.106.028233 (Pubitemid 46147926)
54. Gupta S. K., Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care and STDs 2008 22 2 99 103 2-s2.0-39149101456 10.1089/apc.2007.0052 (Pubitemid 351252586)
55. Coca S., Perazella M. A., Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. American Journal of the Medical Sciences 2002 324 6 342 344 2-s2.0-0036953640 10.1097/00000441-200212000-00011 (Pubitemid 36109329)
56. Labarga P., Barreiro P., Martin-Carbonero L., Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009 23 6 689 696 2-s2.0-64549084582 10.1097/QAD.0b013e3283262a64
57. Ahmad M., Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. Journal of Postgraduate Medicine 2006 52 4 296 297 2-s2.0-33845244144 (Pubitemid 44862772)
58. D'Ythurbide G., Goujard C., Mechai F., Blanc A., Charpentier B., Snanoudj R., Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrology Dialysis Transplantation 2007 22 12 3656 3659 2-s2.0-36749037302 10.1093/ndt/gfm467 (Pubitemid 350212499)
59. Gallant J. E., Deresinski S., Tenofovir disoproxil fumarate. Clinical Infectious Diseases 2003 37 7 944 950 2-s2.0-0142075844 10.1086/378068 (Pubitemid 37267211)
60. Cihlar T., Ho E. S., Lin D. C., Mulato A. S., Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides, Nucleotides and Nucleic Acids 2001 20 4-7 641 648 2-s2.0-0034852408 10.1081/NCN-100002341 (Pubitemid 32821831)
61. Tanji N., Tanji K., Kambham N., Markowitz G. S., Bell A., D'Agati V. D., Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Human Pathology 2001 32 7 734 740 2-s2.0-0034897595 10.1053/hupa.2001.25586 (Pubitemid 32726898)
62. Wever K., van Agtmael M. A., Carr A., Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. Journal of Acquired Immune Deficiency Syndromes 2010 55 1 78 81 2-s2.0-77956621866
63. Herlitz L. C., Mohan S., Stokes M. B., Radhakrishnan J., D'Agati V. D., Markowitz G. S., Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney International 2010 78 11 1171 1177 2-s2.0-78349304725 10.1038/ki.2010.318
64. Post F. A., Moyle G. J., Stellbrink H. J., Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. Journal of Acquired Immune Deficiency Syndromes 2010 55 1 49 57 2-s2.0-77953266037 10.1097/QAI.0b013e3181dd911e
65. Olyaei A. J., DeMattos A. M., Bennett W. M., Renal toxicity of protease inhibitors. Current Opinion in Nephrology and Hypertension 2000 9 5 473 476 2-s2.0-0033849729 10.1097/00041552-200009000-00003
66. Chugh S., Bird R., Alexander E. A., Leonard J. M., Heath-Chiozzi M., Ritonavir and renal failure. The New England Journal of Medicine 1997 336 2 138 2-s2.0-0346998211 10.1056/NEJM199701093360214
67. Krishnan M., Nair R., Haas M., Atta M. G., Acute renal failure in an HIV-positive 50-year-old man. American Journal of Kidney Diseases 2000 36 5 1075 1078 2-s2.0-0033753826
68. Wyatt C. M., Morgello S., Katz-Malamed R., The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney International 2009 75 4 428 434 2-s2.0-59149092579 10.1038/ki.2008.604
69. Mallal S., Phillips E., Carosi G., HLA- B* 5701 screening for hypersensitivity to abacavir. The New England Journal of Medicine 2008 358 6 568 579 2-s2.0-38949196447 10.1056/NEJMoa0706135 (Pubitemid 351214284)
70. Madruga J. V., Cahn P., Grinsztejn B., Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet 2007 370 9581 29 38 2-s2.0-34347327010 10.1016/S0140-6736(07)61047-2 (Pubitemid 47017466)
71. Katlama C., christine.katlama@psl.aphp.fr Clotet B., Mills A., Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antiviral Therapy 2010 15 7 1045 1052 10.3851/IMP1662
72. Hull M. W., Montaner J. S., jmontaner@cfenet.ubc.ca Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Expert Opinion on Pharmacotherapy 2010 11 8 1433 1437 10.1517/14656561003724754
73. Katlama C., christine.katlama@psl.aphp.fr Haubrich R., Lalezari J., Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009 23 17 2289 2300 10.1097/QAD.0b013e3283316a5e
74. Carbone L. G., Bendixen B., Appel G. B., Sulfadiazine-associated obstructive nephropathy occurring in a patient with the acquired immunodeficiency syndrome. American Journal of Kidney Diseases 1988 12 1 72 75 2-s2.0-0023788961
75. Krieble B. F., Rudy D. W., Glick M. R., Clayman M. D., Case report: acyclovir neurotoxicity and nephrotoxicity-the role for hemodialysis. American Journal of the Medical Sciences 1993 305 1 36 39 2-s2.0-0027393253 (Pubitemid 23015289)
76. Kopp J. B., Miller K. D., Mican J. A. M., Crystalluria and urinary tract abnormalities associated with indinavir. Annals of Internal Medicine 1997 127 2 119 125 2-s2.0-0030793476 (Pubitemid 27337395)
77. Izzedine H., Valantin M. A., Daudon M., Mohand H. A., Caby F., Katlama C., Efavirenz urolithiasis. AIDS 2007 21 14 1992 2-s2.0-34548275129 10.1097/QAD.0b013e3282ef792f (Pubitemid 47329785)
78. Gupta S. K., Eustace J. A., Winston J. A., Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases 2005 40 11 1559 1585 2-s2.0-21144445218 10.1086/430257 (Pubitemid 40720806)
79. Daugas E., Plaisier E., Boffa J. J., Acute renal failure associated with immune restoration inflammatory syndrome. Nature Clinical Practice Nephrology 2006 2 10 594 598 2-s2.0-33749047707 10.1038/ncpneph0282 (Pubitemid 44465681)
80. Jehle A. W., Khanna N., Sigle J. P., Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis. Clinical Infectious Diseases 2004 38 4 e32 e35 2-s2.0-10744223309
81. Levey A. S., Coresh J., Bolton K., K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases 2002 39 2 supplement 1 S1 S266 2-s2.0-0036176161
82. Smith H. W., The Kidney: Structure and Function in Health and Disease. The Reliability of Inulin as a Measure of Glomerular Filtration 1951 New York, NY, USA Oxford University Press
83. Barraclough K., Er L., Ng F., Harris M., Montaner J., Levin A., A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron-Clinical Practice 2009 111 1 c39 c48 2-s2.0-57049159821 10.1159/000178978
84. 2 American Journal of Kidney Diseases 2010 56 3 486 495 2-s2.0-77956225926 10.1053/j.ajkd.2010.03.026
85. Bonjoch A., Bayés B., Riba J., Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. Antiviral Research 2010 88 3 347 354 2-s2.0-78650235666 10.1016/j.antiviral.2010.09.015
86. Levey A. S., Stevens L. A., Schmid C. H., A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 2009 150 9 604 612 2-s2.0-65649142017
87. Bostom A. G., Kronenberg F., Ritz E., Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. Journal of the American Society of Nephrology 2002 13 8 2140 2144 2-s2.0-0036069880 10.1097/01.ASN.0000022011.35035.F3 (Pubitemid 34790792)
88. Huang E., Hewitt R. G., Shelton M., Morse G. D., Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 1996 16 2 I 222 229 2-s2.0-0029919264 (Pubitemid 26087932)
89. Smith B. L., Sarnoski T. P., Dennis S., Luke D. R., Failure of predicted creatinine clearance equations in HIV-seropositive patients. International Journal of Clinical Pharmacology Therapy and Toxicology 1992 30 10 394 399 2-s2.0-0026808504
90. Eastwood J. B., Kerry S. M., Plange-Rhule J., Assessment of GFR by four methods in adults in Ashanti, Ghana: the need for an eGFR equation for lean African populations. Nephrology Dialysis Transplantation 2010 25 7 2178 2187 2-s2.0-77954335437 10.1093/ndt/gfp765
91. van Deventer H. E., George J. A., Paiker J. E., Becker P. J., Katz I. J., Estimating glomerular filtration rate in black South Africans by use of the modification of diet in renal disease and Cockcroft-Gault equations. Clinical Chemistry 2008 54 7 1197 1202 2-s2.0-47549107629 10.1373/clinchem.2007.099085 (Pubitemid 352009697)
92. Kuwabara T., Mori K., Mukoyama M., Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney International 2009 75 3 285 294 2-s2.0-58349107121 10.1038/ki.2008.499
93. Bernard A. M., Moreau D., Lauwerys R., Comparison of retinol-binding protein and beta 2-microglobulin determination in urine for the early detection of tubular proteinuria. Clinica Chimica Acta 1982 126 1 1 7 2-s2.0-0020461240 10.1016/0009-8981(82)90356-4 (Pubitemid 13242360)
94. Price R. G., The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clinical Nephrology 1992 38 supplement 1 S14 S19 2-s2.0-0027075199 (Pubitemid 23092540)
95. Hall A. M., Edwards S. G., Lapsley M., Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. American Journal of Kidney Diseases 2009 54 6 1034 1042 2-s2.0-70450222925 10.1053/j.ajkd.2009.07.012
96. Wild S., Roglic G., Green A., Sicree R., King H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 5 1047 1053 2-s2.0-2342466734 10.2337/diacare.27.5.1047 (Pubitemid 38579764)
97. Wanner D. P., Tyndall A., Walker U. A., Tenofovir-induced osteomalacia. Clinical and Experimental Rheumatology 2009 27 6 1001 1003 2-s2.0-76649098300
98. Abu-Aisha H., Elamin S., Peritoneal dialysis in Africa. Peritoneal Dialysis International 2010 30 1 23 28 2-s2.0-77957685619 10.3747/pdi.2008.00226
99. De Beaudrap P., Diallo M. B., Landman R., Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese Cohort (ANRS 1215). AIDS Research and Human Retroviruses 2010 26 11 1221 1227 2-s2.0-78649314704 10.1089/aid.2009.0261
100. Fine D. M., Editorial comment: fanconi syndrome and tenofovir- understanding proximal tubular function. AIDS Reader 2007 17 6 326 327 2-s2.0-34250378753 (Pubitemid 46911173)
101. Tabatabai S., Sperati C. J., Atta M. G., Predictors of complication after percutaneous ultrasound-guided kidney biopsy in HIV-infected individuals: possible role of hepatitis C and HIV co-infection. Clinical Journal of the American Society of Nephrology 2009 4 11 1766 1773 2-s2.0-73449084071 10.2215/CJN.03880609
102. Mcligeyo S. O., Initial experience with CAPD in patients with HIV infection in a developing country. Peritoneal Dialysis International 1992 12 2 267 268 2-s2.0-0026549606
103. Fabian J., Katz I., Gerntholtz T., Goetsch S., Naicker S., Chronic kidney disease in human immunodeficiency virus infection. Panminerva Medica 2007 49 2 51 66 2-s2.0-34547816049
104. Frassetto L. A., Tan-Tam C., Stock P. G., Renal transplantation in patients with HIV. Nature Reviews Nephrology 2009 5 10 582 589 2-s2.0-70349623636 10.1038/nrneph.2009.140
105. Stock P. G., Barin B., Murphy B., Outcomes of kidney transplantation in HIV-infected recipients. The New England Journal of Medicine 2010 363 21 2004 2014 2-s2.0-78549288927 10.1056/NEJMoa1001197
106. Jain A. K. B., Venkataramanan R., Shapiro R., The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transplantation 2002 8 9 841 845 2-s2.0-0035993626 (Pubitemid 35012297)
107. Marfo K., Greenstein S., Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation Proceedings 2009 41 9 3796 3799 2-s2.0-71749116885 10.1016/j.transproceed.2009.06.186
108. Singh J. A., Organ transplantation between HIV-infected patients. The Lancet 2010 375 9713 442 443 2-s2.0-75749083325 10.1016/S0140-6736(09)60338-X
109. Muller E., Kahn D. M., Mendelson M., Renal transplantation between HIV-positive donors and recipients. The New England Journal of Medicine 2010 362 24 2336 2337 2-s2.0-77953694740 10.1056/NEJMc0900837